Donepezil
Brand names: Aricept, Aricept ODT · Generic available · Acetylcholinesterase inhibitor (ChEI)
What is Donepezil?
Donepezil (brand name Aricept) is the most widely prescribed medication for Alzheimer's disease worldwide. It belongs to the class of acetylcholinesterase inhibitors (also called cholinesterase inhibitors or ChEIs) — drugs that enhance cholinergic neurotransmission in the brain by preventing the degradation of the neurotransmitter acetylcholine. It is notable for being the only cholinesterase inhibitor approved by the FDA for all three stages of Alzheimer's disease: mild, moderate, and severe.
Donepezil is available as standard oral tablets and as orally disintegrating tablets (ODT) that dissolve on the tongue without water — a formulation particularly useful for patients who have difficulty swallowing pills. A combination product called Namzaric pairs donepezil with memantine in a single extended-release capsule for patients with moderate-to-severe disease who require both drugs.
What is Donepezil Used For?
Donepezil's primary indication is Alzheimer's disease across its full spectrum of severity, but it is also studied and used in other conditions:
- Mild Alzheimer's disease: Used to address early cognitive symptoms including memory lapses, word-finding difficulties, and mild impairment in complex daily tasks.
- Moderate Alzheimer's disease: Continues to provide benefit as the disease advances; may help with daily functioning and behavioral symptoms in addition to cognition.
- Severe Alzheimer's disease: One of very few treatments with evidence of benefit at this late stage, where patients require substantial assistance with basic activities and have profound cognitive impairment.
- Off-label — Vascular dementia: Dementia caused by reduced blood supply to the brain; donepezil is sometimes used given that many patients have mixed Alzheimer's and vascular pathology.
- Off-label — Lewy body dementia and Parkinson's disease dementia: Cholinergic deficits are prominent in these conditions, and donepezil is used clinically though it is not FDA-approved for these indications.
How Does Donepezil Work?
One of the hallmark pathological features of Alzheimer's disease is the progressive degeneration of neurons in the basal forebrain that produce and release acetylcholine — a neurotransmitter critical for attention, learning, and memory. As these neurons die, acetylcholine levels in the brain's cortex and hippocampus (a key memory-processing region) fall substantially, contributing to the cognitive symptoms of the disease. Donepezil addresses this deficit by blocking the enzyme acetylcholinesterase, which normally breaks down acetylcholine in the synaptic cleft after it has transmitted its signal. By inhibiting this degradation, donepezil allows acetylcholine to persist longer in the synapse and continue stimulating its receptors, partially compensating for the reduced supply of the neurotransmitter.
Importantly, donepezil's inhibition of acetylcholinesterase is reversible — it binds to the enzyme temporarily and can be displaced. It is also highly selective for the enzyme form found in the brain (as opposed to peripheral tissues), which contributes to its relative tolerability compared to older, non-selective cholinesterase inhibitors. However, the drug's effects are symptomatic, not disease-modifying: it does not prevent the ongoing death of cholinergic neurons or slow the accumulation of amyloid plaques and tau tangles that characterize Alzheimer's pathology. Its benefits — typically modest improvements in cognitive test scores and functional assessments — reflect enhanced transmission through the shrinking pool of surviving cholinergic neurons.
Side Effects
Common Side Effects
- Nausea (most common, particularly when starting or increasing the dose)
- Diarrhea
- Vomiting
- Insomnia or vivid dreams (taking the pill in the morning instead of evening can sometimes help)
- Muscle cramps (a cholinergic effect)
- Fatigue and general tiredness
- Anorexia (decreased appetite) and weight loss
- Headache
Serious Side Effects
- Bradycardia and cardiac conduction abnormalities: Acetylcholine slows the heart rate via the vagus nerve. Donepezil can cause clinically significant bradycardia (slow heart rate), heart block, or syncope (fainting), particularly in patients with pre-existing cardiac conditions such as sick sinus syndrome or other supraventricular conduction disturbances. Anyone with heart disease should be carefully evaluated before starting donepezil.
- Syncope (fainting): Can result from the cardiac effects described above, especially in elderly patients. Report any episodes of dizziness, lightheadedness, or fainting.
- Gastrointestinal bleeding: Cholinesterase inhibitors increase gastric acid secretion, which heightens the risk of peptic ulcer disease and GI bleeding, particularly when donepezil is used alongside NSAIDs (ibuprofen, naproxen, aspirin). Patients with a history of peptic ulcers require extra caution.
- Seizures: Rare but reported; the cholinergic effects of donepezil can lower the seizure threshold in susceptible individuals.
- Worsening of urinary obstruction: Cholinergic stimulation increases bladder contractions; donepezil can worsen urinary difficulties in patients with bladder outlet obstruction or benign prostatic hyperplasia.
- Worsening asthma or COPD: Cholinergic effects can cause bronchoconstriction (airway narrowing). Use with caution in patients with obstructive lung disease.
Drug Interactions
Donepezil is metabolized primarily by the liver enzymes CYP2D6 and CYP3A4, making it susceptible to interactions with drugs that affect these pathways. Its cholinergic mechanism also creates important pharmacodynamic interactions.
| Drug / Drug Class | Interaction Type | Effect & What to Do |
|---|---|---|
| Anticholinergic drugs (diphenhydramine, oxybutynin, tolterodine, tricyclic antidepressants) | Pharmacodynamic (directly opposing) | Anticholinergics block acetylcholine receptors, directly counteracting donepezil's therapeutic effect. This combination effectively cancels out the cognitive benefit of donepezil and should be avoided when possible. The combination is unfortunately common in elderly patients who are prescribed bladder medications or antihistamines. |
| Beta-blockers (metoprolol, atenolol, carvedilol) | Pharmacodynamic (additive) | Both beta-blockers and donepezil slow the heart rate. Combining them increases the risk of clinically significant bradycardia, particularly at higher donepezil doses. Heart rate should be monitored. |
| NSAIDs (ibuprofen, naproxen, aspirin) | Pharmacodynamic (additive GI risk) | Donepezil increases gastric acid secretion, while NSAIDs damage the protective stomach lining. Together they substantially increase the risk of peptic ulcer disease and GI bleeding. Discuss safer pain-relief alternatives with the prescriber if possible. |
| CYP3A4 / CYP2D6 inducers (rifampin, carbamazepine, phenytoin, St. John's Wort) | Pharmacokinetic (reduced donepezil levels) | These drugs speed up the liver enzymes that metabolize donepezil, reducing its blood levels and potentially diminishing its clinical effectiveness. Dose adjustment may be necessary. |
| Succinylcholine and other neuromuscular blocking agents | Pharmacodynamic (enhanced neuromuscular blockade) | Donepezil can prolong and intensify the muscle-relaxing effects of succinylcholine (used in anesthesia), potentially causing prolonged paralysis. Surgeons and anesthesiologists must be informed of donepezil use before any surgical procedure. |
Who Should Not Take Donepezil?
- People with known hypersensitivity to donepezil, piperidine derivatives, or any component of the formulation
- Patients with sick sinus syndrome or other supraventricular cardiac conduction disturbances without a functioning pacemaker (significant bradycardia risk)
- Caution in patients with active or recently treated peptic ulcer disease — risk of GI bleeding is elevated
- Caution in patients with asthma or chronic obstructive pulmonary disease (COPD) — may worsen bronchoconstriction
- Caution in patients with bladder outlet obstruction or benign prostatic hyperplasia — urinary symptoms may worsen
- Always inform the anesthesiologist before any surgical procedure — donepezil prolongs the effects of certain anesthetic muscle relaxants
Frequently Asked Questions
How long does donepezil take to work?
Some patients and caregivers notice subtle improvements in alertness, engagement, or daily functioning within the first few weeks of starting donepezil. However, formal cognitive assessments in clinical trials typically measure benefit at 12–24 weeks. It is important to understand that the goal of treatment is often to slow the rate of cognitive decline rather than to produce dramatic reversal of symptoms — improvement may be subtle or may simply mean the patient worsens more slowly than they would have without the drug.
What should I do about the nausea from donepezil?
Nausea and GI side effects from donepezil are most common when starting the medication or increasing the dose. They are often temporary and diminish over the first few weeks as the body adjusts. Taking donepezil with food may help, though this is not a strict requirement. If nausea is severe or persistent, speak with the prescriber — they may suggest a slower dose titration schedule or a temporary dose reduction. Do not stop the medication abruptly without medical guidance.
Can donepezil cause insomnia?
Yes — insomnia and unusually vivid dreams are recognized side effects of donepezil. This appears to be related to its cholinergic activity during sleep, particularly REM sleep. Taking donepezil in the morning rather than at bedtime (as is sometimes prescribed) may reduce sleep-related side effects in some patients, though this is a matter to discuss with the prescriber as timing can affect tolerability differently in different individuals.
Is donepezil the same as Aricept?
Yes. Aricept is the original brand name under which donepezil was marketed by Eisai and Pfizer. The patent has expired and donepezil is now widely available as a much less expensive generic medication. Both the brand and generic versions contain the same active ingredient (donepezil hydrochloride) and are therapeutically equivalent. The orally disintegrating tablet (ODT) formulation is also available in generic form.
Related Drugs
Other medications used in Alzheimer's disease and dementia: